INDV
Indivior Pharmaceuticals Inc
$37.53
+0.07
(+0.19%)
Mkt Cap
4.68B
Volume
1,006,924
52W Range
11.49-41
Sector
Healthcare
Beta
1.20
EPS (TTM)
2.01
P/E Ratio
18.67
Revenue (TTM)
1.29B
Rev Growth (5Y)
+13.9%
EPS Growth (5Y)
+25.3%
AlphaVal · Fair Value
$29.73
Overvalued · Moderate
26.2% above fair value
AlphaQuality · Grade · Gated
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Company Description
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.19B | 1.09B | 901.00M | 791.00M | 647.00M | 785.00M | 959.92M | 1.15B | 968.89M |
| Net Income | 210.00M | 2.00M | (129.00M) | (44.00M) | 205.00M | (148.00M) | 134.00M | 262.67M | 60.92M | 32.05M |
| EPS | 1.68 | 0.02 | 0.01 | -0.37 | 1.38 | -1.08 | 0.95 | 1.81 | 0.42 | 0.22 |
| Free Cash Flow | (93.00M) | 7.00M | (353.00M) | (9.00M) | 319.00M | (197.00M) | 144.00M | 250.25M | 264.70M | 340.67M |
| FCF / Share | -0.74 | 0.05 | -2.57 | -0.06 | 2.19 | -1.34 | 0.99 | 1.72 | 1.84 | 2.37 |
| Operating CF | (27.00M) | 36.00M | (300.00M) | (4.00M) | 353.00M | (193.00M) | 151.00M | 289.41M | 309.87M | 372.72M |
| Total Assets | 1.20B | 1.32B | 1.76B | 1.78B | 1.83B | 1.53B | 1.65B | 1.55B | 1.44B | 1.21B |
| Total Debt | 351.00M | 375.00M | 283.00M | 277.00M | 286.00M | 285.00M | 293.00M | 241.00M | 482.00M | 535.00M |
| Cash & Equiv | 195.00M | 319.00M | 316.00M | 778.18M | 1.10B | 858.00M | 1.06B | 924.00M | 863.00M | 692.00M |
| Book Value | (98.00M) | (348.00M) | (191.00M) | 51.28M | 203.00M | 82.00M | 209.00M | 66.00M | (203.00M) | (295.00M) |
| Return on Equity | N/A | N/A | N/A | -0.86 | 1.01 | -1.80 | 0.64 | 3.98 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 317.00M | 358.00M | 314.00M | 302.00M | 266.00M | 299.00M | 307.00M | 299.00M | 284.00M | 293.00M | 271.00M | 276.00M |
| Net Income | 89.00M | 102.00M | 42.00M | 18.00M | 47.00M | 59.00M | 4.00M | (97.00M) | 61.00M | 54.00M | (135.00M) | 39.00M |
| EPS | 0.71 | 0.82 | 0.34 | 0.14 | 0.38 | 0.45 | 0.03 | -0.72 | 0.45 | 0.39 | -0.94 | 0.29 |
| Free Cash Flow | (29.00M) | (245.00M) | (59.00M) | 148.38M | 70.00M | (21.49M) | (1.00M) | 83.83M | (56.75M) | (283.62M) | 19.12M | (20.86M) |
| FCF / Share | -0.23 | -1.96 | -0.47 | 1.20 | 0.57 | -0.17 | -0.01 | 0.62 | -0.42 | -2.07 | 0.14 | -0.15 |
| Operating CF | (9.00M) | (221.00M) | (39.00M) | 166.04M | 75.00M | (5.65M) | 8.00M | 87.83M | (54.76M) | (279.72M) | 21.17M | (19.83M) |
| Total Assets | 1.20B | 1.20B | 1.42B | 1.45B | 1.38B | 1.32B | 1.46B | 1.54B | 1.45B | 1.76B | 1.85B | 1.73B |
| Total Debt | 509.00M | 351.00M | 356.00M | 366.00M | 370.00M | 375.00M | 284.00M | 281.04M | 278.79M | 283.00M | 277.00M | 281.00M |
| Cash & Equiv | 175.00M | 195.00M | 445.00M | 510.00M | 372.00M | 319.00M | 288.00M | 302.05M | 247.81M | 316.00M | 610.00M | 592.00M |
| Book Value | (144.00M) | (98.00M) | (207.00M) | (258.00M) | (286.00M) | (348.00M) | (167.00M) | (121.02M) | 9.99M | (191.00M) | (24.00M) | 117.00M |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6.10 | N/A | N/A | 0.33 |
INDV News
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Bears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' Now
Indivior to Participate in Upcoming Investor Conferences
Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally
3 Best Momentum Stocks to Buy Now for Big Upside in May 2026
Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?
Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know
Best Momentum Stock to Buy for May 5th
Indivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript